{"id":8148,"date":"2022-05-02T14:57:15","date_gmt":"2022-05-02T12:57:15","guid":{"rendered":"https:\/\/ferd.no\/?p=8148"},"modified":"2022-05-02T15:27:47","modified_gmt":"2022-05-02T13:27:47","slug":"ferd-acquires-33-of-the-diagnostics-company-aidian","status":"publish","type":"post","link":"https:\/\/ferd.no\/en\/capital-en\/ferd-acquires-33-of-the-diagnostics-company-aidian\/","title":{"rendered":"Ferd acquires 33% of the diagnostics company Aidian"},"content":{"rendered":"<p><em>\u00abFinnish Aidian has built a globally leading position in point-of-care diagnostics. The company\u2019s instruments and tests are an important part of the solution to meet global health challenges. Together with the majority shareholder Nordstjernan, we want to develop the company\u2019s position as a leading European diagnostic player in point-of-care diagnostics and analysis,\u201d<\/em> says CEO of Ferd, Morten Borge.<\/p>\n<p>Earlier this year, the Swedish family-controlled investment company Nordstjernan bought 100% of the shared In Aidian. Ferd now buys 33% of the shares and thus enters as a minority owner.<\/p>\n<p><em>\u00abWe are delighted to have Ferd as a partner in Aidian\u2019s further development and growth. <\/em><em>Nordstjernan and Ferd have a lot in common, both being family-controlled companies that think long-term about our investments. In addition, we both see great potential in the health sector,<\/em>\u201d says the CEO of Nordstjernan, Peter Hofvenstam.<\/p>\n<p>The parties have agreed that the terms of the transaction will not be published.<\/p>\n<p>Contact information:<\/p>\n<p>Ferd AS:<\/p>\n<p>Morten Borge, CEO<\/p>\n<p>Tlf: +47 90169291<\/p>\n<p>&nbsp;<\/p>\n<p>Nordstjernan AB:<\/p>\n<p>Stefan Stern<\/p>\n<p>Tlf::\u00a0 +46 70 636 74 17<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Finnish company Aidian develops, manufactures and sells medical instruments and tests that are used in, among other things, the primary health service to provide fast and reliable results. Aidian\u2019s range of tests addresses several global health issues such as antimicrobial resistance (AMR), diabetes and colon cancer. One of their foremost priority areas are tests aimed at reducing unnecessary prescribing of antibiotics, which drives the growing threat of antimicrobial resistance and antibiotic-resistant bacteria.  <\/p>\n","protected":false},"author":14,"featured_media":8149,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[167],"tags":[],"class_list":["post-8148","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-capital-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/ferd.no\/en\/wp-json\/wp\/v2\/posts\/8148","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ferd.no\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ferd.no\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ferd.no\/en\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/ferd.no\/en\/wp-json\/wp\/v2\/comments?post=8148"}],"version-history":[{"count":0,"href":"https:\/\/ferd.no\/en\/wp-json\/wp\/v2\/posts\/8148\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ferd.no\/en\/wp-json\/wp\/v2\/media\/8149"}],"wp:attachment":[{"href":"https:\/\/ferd.no\/en\/wp-json\/wp\/v2\/media?parent=8148"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ferd.no\/en\/wp-json\/wp\/v2\/categories?post=8148"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ferd.no\/en\/wp-json\/wp\/v2\/tags?post=8148"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}